CDK4 and hepatocellular carcinoma: Liangtao Ye et al.164 found that copanlisib led to cell cycle arrest by affecting the cyclin D1/CDK4/6 signaling pathway, which significantly reduced cell activity and inhibited the colony forming process in various natural and sorafenib-resistant HCC cells.